TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Connect® MDS/AML Disease Registry

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors

Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer

Study of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer

An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)